This study aims to develop the quantitative biomarker to establish the individualized strategy in stroke rehabilitation. Brain-derived neurotrophic factor (BDNF) acts on certain neurons of the central nervous system (CNS) helping to support the survival of existing neurons, and encourage the growth and differentiation of new neurons and synapses. BDNF in CNS can be assessed by analysing serum BDNF. The final objective of this study is to demonstrate a role of biomarker of BDNF in stroke rehabilitation to establish the individualized strategy.

Serum BDNF, proBDNF and MMP-9 in all participants will be measured before and after the comprehensive inpatient rehabilitation during subacute stroke phase. At 3 months after stroke onset, serum BDNF, proBDNF and MMP-9 will also be measured.

In addition, motor impairment with Fugl-Meyer assessement will be assessed at same time points with serum analysis.

We will compare potential serum biomarkers with motor impairment in stroke patients

Inclusion Criteria:

• unilateral stroke patients
• admission to the rehabilitation department before 1 month after stroke onset
• mild to severe motor impairment at time of transferring to the rehabilitation department

Exclusion Criteria:

• Progressive or unstable stroke
• Pre-existing and active major neurological disease
• Pre-existing and active major psychiatric disease
• Advanced liver, kidney, cardiac, or pulmonary disease
• A terminal medical diagnosis consistent with survival < 1 year)
• Pregnant or lactating woman

Subacute stroke patients who were received the comprehensive inpatients rehabilitation

There is no plan to make IPD available to other researchers.